Alembic Global Advisors is an independent equity research firm offering differentiated, experienced financial analysis on a variety of global industrial sectors. Our goal is to provide high quality, proprietary and actionable research into company, industry and broader macro trends on a truly global level.
Since its founding in 2009, Alembic has expanded from its core global chemical coverage to the aerospace & defense sector. Our analysts have been recognized by industry publications Institutional Investor, FT/Starmine and Extel.2 research analysts covering 35 companies across 3 industries (Chemicals and Aerospace & Defense). Our coverage list continues to grow as we remain focused on delivering our best-in-class research product.
Through our corporate access events we provide unique opportunities to meet with a select group of industry leaders, offering the chance to gain unique insights from people operating at the highest levels of their respective industries.
In addition to highly analytical deep dive research surrounding our specific equity coverage, we provide our macro view of each industry against the global backdrop of current events and how we see them shaping the future. We leverage our various areas of expertise to produce a collaborative cross-sector research product. This non-siloed approach allows us to maximize our areas of expertise, ultimately achieving a more dynamic and in-depth level of insight.
Not a client? Please contact Stephen Matthews – stephen.matthews@alembicglobal.com – to learn more about our research subscription offerings.
Access is limited to Alembic Global Advisors clients.
Key Points We’re raising our forecast and target price for ATI post the firm’s 1Q26 earnings report, and we’re reiterating our Overweight rating on the shares. Our target price rises ......
Key Points Emerging MDI pricing momentum and tighter supply dynamics support the view that Huntsman earnings are positively inflecting from trough levels Normalized MDI margins and utilization rates could drive ......
Key Points We’re reiterating our Overweight rating on shares of RBC after Friday’s 4QFY26 earnings report, and we’re raising our target price by USD32 to USD671. We’ve also raised our ......
Key Points We spent time with MRCY’s management team last Thursday during an NYC non-deal road show, and we came away more confident than ever that the firm’s brightest days ......
Key Points We are updating our forecast for LHX post 1Q26 earnings and we’re lowering our target price by USD30 to USD406 as we become a little more conservative on ......
Key Points TiO2 fundamentals improving as destocking fades, pricing rises, and margins rebound Capacity cuts, higher Chinese costs, and anti-dumping actions tightening global supply TROX is our preferred name in ......